Cryo-Save Group N.V. - Announcement determination of stock dividend ratio
(Thomson Reuters ONE) -
Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading
international family stem cell bank, announced today the determination of the
stock ratio of the dividend for the year ended 31 December 2010 as approved by
the Annual General Meeting of Shareholders on 18 May 2011.
The average price during the period 20 May 2011 up to and including 3 June 2011
was ? 5.07. The number of dividend rights giving entitlement to one Cryo-Save
Group N.V. share has on 3 June 2011 (after market) been set at 72 (or at the
choice of the banks or stockbroker where a shareholder holds its shares 7,200
dividend rights gives entitlement to 100 shares). Payment of stock dividend is
only made in whole shares; fractions of shares are settled in cash.
The Group announces that shareholders wish to receive a distribution in shares
for 29% of the total dividend.
The cash distribution will be payable and the shares will be delivered as per
16 June 2011.
In this context a total of approximately 37,000 shares will be issued, charged
to the share premium reserve, representing a Euro equivalent of approximately
?187,000. The cash dividend will amount to ?463,000 before withholding 15%
dividend withholding tax.
Paying Agent: Kempen & Co N.V.
Enquiries:
Cryo-Save Group, Arnoud van Tulder, Chief Executive Officer, + 31 (0)
575 548 998
SPJ Financiële Communicatie (The Netherlands), Kees Jongsma/Leon Melens, +31
(0)20 647 8181
Daniel Stewart & Company plc (UK), Sean Lunn, + 44 (0) 20 7776 6550
College Hill (UK), Rozi Morris/ Adrian Duffield, + 44 (0) 20 7457 2020
Kempen & Co N.V., Dick Siemensma, + 31 (0) 20 348 9554
Capita registrars (UK), Rachel Sellers, + 44 (0) 14 8460 0931
Free footage is available on www.videobankonline.com.
About Cryo-Save (www.cryo-save.com/group)
Cryo-Save, the leading international family stem cell bank, already stores
175,000 samples from cord blood and umbilical cord tissue for newborns and
adipose tissue for adults. These stem cells can mean the difference between life
and death in the case of future threats to the health of the donors. There are
already several diseases that can be cured by the use of stem cells, and the
number of treatments will only increase. Driven by its international business
strategy, Cryo-Save is now represented in 40 countries on three continents, with
ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India
and France (validation in progress).
Please click here for full press release in PDF:
http://hugin.info/143308/R/1521216/457380.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cryo-Save Group N.V. via Thomson Reuters ONE
[HUG#1521216]
Unternehmensinformation / Kurzprofil:
Datum: 03.06.2011 - 19:24 Uhr
Sprache: Deutsch
News-ID 55292
Anzahl Zeichen: 3460
contact information:
Town:
Zutphen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 261 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cryo-Save Group N.V. - Announcement determination of stock dividend ratio"
steht unter der journalistisch-redaktionellen Verantwortung von
Cryo-Save Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
